Low oxytocin levels in hair are linked to reduced empathy and may affect hair growth. Cinnamic acid can promote hair growth by activating oxytocin receptors.
The conversation discusses why CB-03-01, a potential hair loss treatment, isn't widely discussed despite evidence of its effectiveness and safety. Some users mention other treatments like melatonin, procianidin b2, and RU58841, debating their effectiveness and safety.
Pelage executives' hairlines were discussed, with speculation about them using PP405 for hair regrowth. Concerns were raised about using untested drugs, with some suggesting executives might not risk using them without safety data.
PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.
A 17-year-old is stressed about mild male pattern baldness and is considering treatments like minoxidil and finasteride but is concerned about starting finasteride too young. Users suggest starting with minoxidil and considering finasteride at 18, while emphasizing the importance of consulting a doctor and not obsessing over hair loss.
An 18-year-old is using a high-dose treatment for hair loss, including 2.5 mg dutasteride, topical minoxidil, and injectable GHK-Cu, despite minimal hair loss. Many users suggest reducing the dutasteride dose due to potential side effects and recommend starting with finasteride instead.
The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.
PP405 from Everychem is likely fake and potentially harmful, with concerns about its stability and the risk of using the wrong MPC inhibitor, which could damage hair follicles. The real PP405 was studied under strict conditions, and DIY attempts are discouraged due to unknown formulation and quality control.
A 28-year-old male shares progress using 5mg Minoxidil and 0.5mg Dutasteride for hair growth, encouraging the use of these treatments. Users discuss side effects like increased facial hair and debate the effectiveness of treatments within three months.
Finasteride does not negatively impact athletic performance and may slightly increase testosterone levels. It is banned in some sports like the NBA due to its potential to mask steroid use.
The user experienced hair thinning from chromium and alpha lipoic acid supplements, which stopped after discontinuing them. Someone mentioned this could be telogen effluvium, a temporary condition.
P5P supplementation helped reverse finasteride side effects, particularly by lowering prolactin levels and restoring sensitivity. The user experienced significant improvement within a day and full recovery in a few days.
12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.
The conversation is about the prevalence of baldness among young men and the potential factors contributing to it. Specific treatments mentioned include minoxidil and finasteride.
The user is experiencing hair thinning on the sides and back of the head while the top remains thick. A reply suggests it might be retrograde alopecia.
The user experienced hair density loss after increasing finasteride dosage from 3x to 7x a week. It was suggested that this might be a temporary adjustment issue, and adding minoxidil could help.
RU and Pyri block androgen receptors to prevent hair loss but may also hinder hair regrowth since they prevent testosterone, which can stimulate hair growth, from binding to these receptors. The user is questioning if this understanding is correct.
Finasteride and dutasteride can cause psychiatric side effects like depression and suicidal thoughts in some users, especially those with a history of mental health issues. While some users experience positive hair growth results, others face severe psychological effects, raising concerns about their safety and the need for careful monitoring.
The user started using topical latanoprost and dutasteride, experiencing significant hair shedding and scalp itchiness, possibly due to an allergic reaction. They are considering stopping the treatment if the shedding is linked to an allergy.
A 22-year-old has been using topical finasteride and minoxidil with microneedling for hair loss, considering switching to oral finasteride or dutasteride due to slowed progress. Recent changes in application technique and increased microneedling frequency seem to have led to noticeable hair regrowth, prompting reconsideration of switching treatments.
A male with early-stage hair loss experienced severe side effects, including sexual dysfunction from finasteride and increased heart rate and fatigue from high-dose minoxidil, leading to discontinuation of both treatments. He is now relying on DHT-blocking shampoos and awaiting new treatments.
Switching from finasteride and topical minoxidil to dutasteride and oral minoxidil caused a major hair shed, exacerbated by moving stress. Dutasteride may take months to fully integrate, and adding finasteride might help with hair protection during this transition.
Dutasteride improved the user's hair thickness and health, slowed body and facial hair growth, and enhanced skin condition. The user also reported feeling energetic with a slight decrease in libido but no issues with sexual function.
Some users of RU-58841 report cardiovascular symptoms like heart palpitations and chest tightness, which may be linked to its metabolites causing lung disease. The safety of RU-58841 is uncertain due to lack of long-term data and concerns about product purity, especially from gray market sources.
The user is frustrated with hair loss despite using finasteride and is considering a hairpiece as a solution. Suggestions include trying a buzz cut, considering dutasteride or oral minoxidil, and addressing potential dietary issues.
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
Dutasteride can lead to increased cholesterol and liver fat. The user is reconsidering its use due to high cholesterol and lipid levels despite a healthy lifestyle.
New hair loss treatments include topical and gel formulations combining finasteride and dutasteride, with added caffeine and melatonin. The user reports positive results from using topical dutasteride.